Tenofovir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318800

CAS#: 147127-20-6 (Tenofovir)

Description: Tenofovir is an antiretroviral medication used to prevent and treat HIV/AIDS and to treat chronic hepatitis B.[1] The active substance is tenofovir, while tenofovir disoproxil is a prodrug that is used because of its better absorption in the gut.

Chemical Structure

img
Tenofovir
CAS# 147127-20-6 (Tenofovir)
Instruction

Theoretical Analysis

MedKoo Cat#: 318800
Name: Tenofovir
CAS#: 147127-20-6 (Tenofovir)
Chemical Formula: C9H14N5O4P
Exact Mass: 287.08
Molecular Weight: 287.216
Elemental Analysis: C, 37.64; H, 4.91; N, 24.38; O, 22.28; P, 10.78

Price and Availability

Size Price Availability Quantity
1g USD 150 Ready to ship
2g USD 200 Ready to ship
5g USD 350 Ready to ship
10g USD 550 Ready to ship
25g USD 1050 Ready to ship
Bulk inquiry

Related CAS #: 147127-20-6 (Tenofovir)   206184-49-8 (hydrate)  

Synonym: GS1275; GS-1275; GS 1275; Tenofovir; TFV gel; PMPA gel

IUPAC/Chemical Name: (R)-(((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid

InChi Key: SGOIRFVFHAKUTI-ZCFIWIBFSA-N

InChi Code: InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1

SMILES Code: C[C@@H](OCP(O)(O)=O)CN1C=NC2=C(N)N=CN=C12

Appearance: White to off-white solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 147127-20-6, 206184-49-8 (hydrate), 379270-37-8 (Tenofovir Alafenamide), 379270-38-9 (Tenofovir alafenamide monofumarate), 1276030-80-8 (Tenofovir disoproxil maleate), 1392275-56-7 (Tenofovir Alafenamide fumarate), 1453166-76-1 (Tenofovir disoproxil phosphate), 1637632-97-3 (Tenofovir disoproxil succinate),

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 2.6 9.12
PBS (pH 7.2) 2.5 8.70
Water 2.0 6.96

Preparing Stock Solutions

The following data is based on the product molecular weight 287.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Chen L, Wang X, Zhang Q, Gong J, Shen S, Yin W, Hu H. Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. Gastroenterol Res Pract. 2016;2016:7214020. doi: 10.1155/2016/7214020. Epub 2016 Jan 11. Review. PubMed PMID: 26880896; PubMed Central PMCID: PMC4737451.

2: Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. Review. PubMed PMID: 26640223.

3: Hemkens LG, Ewald H, Santini-Oliveira M, Bühler JE, Vuichard D, Schandelmaier S, Stöckle M, Briel M, Bucher HC. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015 Oct;16(5):178-89. doi: 10.1179/1945577115Y.0000000004. Review. PubMed PMID: 26395328.

4: Prinapori R, Di Biagio A. Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS. Patient Prefer Adherence. 2015 Aug 24;9:1213-8. doi: 10.2147/PPA.S88490. eCollection 2015. Review. PubMed PMID: 26345643; PubMed Central PMCID: PMC4556264.

5: Kabbara WK, Ramadan WH. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. J Infect Public Health. 2015 Sep-Oct;8(5):409-17. doi: 10.1016/j.jiph.2015.04.020. Epub 2015 May 19. Review. PubMed PMID: 26001757.

6: Raffe S, Fisher M. The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):427-35. doi: 10.1517/17425255.2015.997207. Epub 2015 Jan 2. Review. PubMed PMID: 25553805.

7: Moss DM, Neary M, Owen A. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol. 2014 Nov 11;5:248. doi: 10.3389/fphar.2014.00248. eCollection 2014. Review. Erratum in: Front Pharmacol. 2015;6:18. PubMed PMID: 25426075; PubMed Central PMCID: PMC4227492.

8: Deeks ED. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection. Drugs. 2014 Nov;74(17):2079-95. doi: 10.1007/s40265-014-0318-1. Review. PubMed PMID: 25352394.

9: Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015 Jan 15;60(2):275-8. doi: 10.1093/cid/ciu798. Epub 2014 Oct 13. Review. PubMed PMID: 25313254.

10: Aurpibul L, Puthanakit T. Review of tenofovir use in HIV-infected children. Pediatr Infect Dis J. 2015 Apr;34(4):383-91. doi: 10.1097/INF.0000000000000571. Review. PubMed PMID: 25247583.

11: Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol. 2014 Jun 21;20(23):7169-80. doi: 10.3748/wjg.v20.i23.7169. Review. PubMed PMID: 24966587; PubMed Central PMCID: PMC4064062.

12: Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014 Sep;70(9):1029-40. doi: 10.1007/s00228-014-1712-z. Epub 2014 Jun 25. Review. PubMed PMID: 24958564.

13: Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014 Jun 6;9(6):e98865. doi: 10.1371/journal.pone.0098865. eCollection 2014. Review. PubMed PMID: 24905092; PubMed Central PMCID: PMC4048232.

14: McConville C, Boyd P, Major I. Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. Clin Med Insights Womens Health. 2014 Feb 13;7:1-8. doi: 10.4137/CMWH.S10353. eCollection 2014. Review. PubMed PMID: 24741339; PubMed Central PMCID: PMC3988671.

15: MacBrayne CE, Blum JD, Kiser JJ. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery. Ann Pharmacother. 2014 Jun;48(6):816-9. doi: 10.1177/1060028014525034. Epub 2014 Mar 10. Review. PubMed PMID: 24615629.

16: Manzardo C, Gatell JM. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment. AIDS Rev. 2014 Jan-Mar;16(1):35-42. Review. PubMed PMID: 24584107.

17: Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, Baer R, Sevastos J, Abbas R, Boyd MA. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Res Ther. 2014 Nov 10;11:35. doi: 10.1186/1742-6405-11-35. eCollection 2014. Review. PubMed PMID: 25745499; PubMed Central PMCID: PMC4350301.

18: Coutinho B, Prasad R. Emtricitabine/tenofovir (Truvada) for HIV prophylaxis. Am Fam Physician. 2013 Oct 15;88(8):535-40. Review. PubMed PMID: 24364575.

19: Perry CM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults. Drugs. 2014 Jan;74(1):75-97. doi: 10.1007/s40265-013-0158-4. Review. PubMed PMID: 24338165.

20: Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013 Oct;24(10):1519-27. doi: 10.1681/ASN.2012080857. Epub 2013 Sep 19. Review. PubMed PMID: 24052632; PubMed Central PMCID: PMC3785270.